Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Head & Neck 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Taxoids × Head & Neck × Clear all
NCT05726370 2025-06-22

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
28 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡